Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Eurofins Scientific SE
  6. News
  7. Summary
    ERF   FR0014000MR3


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eurofins Scientific : Credit Presentation November 2021

11/26/2021 | 05:50am EST

CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its affiliates. No part of it may be used, circulated, quoted, or reproduced for distribution outside companies belonging to the Eurofins Group. If you are

not the intended recipient of this document, you are hereby notified that the


circulation, quoting,

or reproducing of


document is strictly prohibited and


be unlawful. Photo

images on this page


the copyrighted property of 123RF Limited.


Credit Presentation

24 November 2021



This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever.

The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain time. Forward looking statements and estimates represent the judgement of Eurofins Scientific's management and involve risks and uncertainties including, but not limited to, risks associated with the inherent uncertainty of research, product/service development and commercialisation, the impact of competitive products and services, patents and other risk uncertainties, including those detailed from time to time in period reports, including prospectus and annual reports filed by Eurofins Scientific with the Luxembourg Stock Exchange and regulatory authorities, that can cause actual results to differ materially from those projected. Eurofins Scientific expressly disclaims any obligation or intention to release publicly any updates or revisions to any forward looking statement or estimate.

Eurofins provides in the Income Statement certain alternative performance measures (non-IFRS information as "Adjusted Results and Separately Disclosed Items") that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. (Please refer to description of these terms in the Company's Annual Report). The management believes that providing this information enhances investors' understanding of the company's core operating results and future prospects, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or objectives and to the performance of our competitors. This information should be considered in addition to, but not in lieu of, information prepared in accordance with IFRS. These APMs are described in more detail in the Condensed Interim Consolidated Financial Statements for the period ended 30 June 2021 in Note 1 and in the Consolidated Financial Statements 2020 in Notes 1.27 and 1.28.



  1. Eurofins at a glance
  1. Market & Strategic Positioning
  1. Commitment to ESG

IV. Finance & Outlook


I. Eurofins at a glance


Key operational highlights (1/3)

  • Continued strong growth across business lines and geographies
  • Global demand for BioPharma services remains very strong
  • Pharmaceutical companies continue to outsource increasing amount of testing services and Eurofins is actively expanding capacity across its laboratory network in the U.S., Europe and Asia
  • In Europe, PFAS testing in food is increasing significantly as a result of stricter safety thresholds set by EFSA regulations
  • TruGraf® continues to show significant growth in sample volumes (+46% in Q3 2021 vs. Q2 2021)
  • Eurofins leadership and teams were delighted to join the large cap CAC 40 Index on September 17

1 Eurofins Transplant Genomics Inc.



Eurofins Scientific SE published this content on 24 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 November 2021 10:49:05 UTC.

ę Publicnow 2021
01/21EUROFINS SCIENTIFIC : Inside Information / Operations of the issuer (acquisitions, sales....
01/17EUROFINS SCIENTIFIC : Managers' transactions - Director/PDMR Shareholding
01/14Keysight Technologies' Test Tools Picked for 5G Device Validation Services in Taiwan
01/11Eurofins CDMO Expands Spray Drying Capabilities
01/11EUROFINS SCIENTIFIC : Managers' transactions - Director/PDMR Shareholding
01/10EUROFINS SCIENTIFIC : Shares in Issue
01/10European shares slide as rising yields hurt tech stocks
01/07EUROFINS SCIENTIFIC : Managers' transactions - Director/PDMR Shareholding
2021Predilife Taps Eurofins to Conduct Genetic Testing of Saliva Samples
2021EUROFINS SCIENTIFIC : Managers' transactions - Director/PDMR Shareholding
More news
Analyst Recommendations on EUROFINS SCIENTIFIC SE
More recommendations
Sales 2021 6 534 M 7 409 M 7 409 M
Net income 2021 801 M 908 M 908 M
Net Debt 2021 2 152 M 2 440 M 2 440 M
P/E ratio 2021 22,2x
Yield 2021 1,03%
Capitalization 17 195 M 19 502 M 19 499 M
EV / Sales 2021 2,96x
EV / Sales 2022 3,06x
Nbr of Employees 55 000
Free-Float -
Duration : Period :
Eurofins Scientific SE Technical Analysis Chart | ERF | FR0014000MR3 | MarketScreener
Technical analysis trends EUROFINS SCIENTIFIC SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 89,44 €
Average target price 112,00 €
Spread / Average Target 25,2%
EPS Revisions
Managers and Directors
Gilles G. Martin Chairman & Chief Executive Officer
Laurent Lebras Director-Group Finance & Administration
Christian Wurst Chief Operating Officer-Food & Environment Testing
Stuart Anderson Independent Non-Executive Director
FÚrÚchtÚ Pouchantchi Independent Non-Executive Director